[Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Patients with epidermal growth factor receptor (EGFR) mutations often benefit from tyrosine kinase inhibitors (TKIs).
• Acquired resistance to TKIs is a significant clinical challenge, limiting long-term treatment efficacy.
• Common resistance mechanisms include secondary EGFR mutations, MET amplification, and histologic transformation.

Purpose of the Study:

• To investigate the role of gene fusions as a mechanism of acquired resistance to EGFR-TKIs.
• To explore the potential of targeting gene fusions in overcoming EGFR-TKI resistance.

Main Methods:

• Review of clinical cases and in vitro/in vivo experimental data.
• Analysis of gene fusion events (RET, BRAF, ALK) in EGFR-TKI resistant models.

Main Results:

• Gene fusions, including RET, BRAF, and ALK, are identified as a less common (around 1%) but significant mechanism of acquired resistance to EGFR-TKIs.
• Clinical and experimental evidence supports the involvement of gene fusions in EGFR-TKI resistance.

Conclusions:

• Gene fusions represent an emerging mechanism contributing to acquired resistance in EGFR-TKI treated patients.
• Combined inhibition of EGFR and specific gene fusions presents a promising therapeutic avenue.
• Understanding gene fusions is crucial for developing advanced diagnostic and treatment strategies for EGFR-TKI resistance.